ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 1705 • 2019 ACR/ARP Annual Meeting

    Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?

    Priscila Dias Cardoso Ribeiro 1, Eduarda Bonelli Zarur 1, Flávia Maria Matos Melo Campos Peixoto 1, Pedro Matos 1, Pedro Paulo de Alcantara Pedro 1, Rywka Tenenbaum Medeiros Golebiovsk 1, Livia Dutra 2 and Alexandre Wagner de Souza3, 1UNIFESP-EPM, Sao Paulo, Sao Paulo, Brazil, 2Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, 3UNIFESP-EPM, São Paulo, Sao Paulo, Brazil

    Background/Purpose: Neurologic involvement is one of the most serious cause of long-term morbidity and mortality in Behçet’s disease (BD). To date, no controlled trials have…
  • Abstract Number: 1706 • 2019 ACR/ARP Annual Meeting

    HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease

    Joice Belem 1, Ana Maria Fraga 2, Luís Eduardo Coelho Andrade 1 and Alexandre Wagner de Souza1, 1UNIFESP-EPM, São Paulo, Sao Paulo, Brazil, 2Fleury Group, São Paulo, Sao Paulo, Brazil

    Background/Purpose: HLA-B*51 is considered the genetic marker mostly associated with Behçet's disease (BD), mainly in countries of the silk route, where its prevalence ranges from…
  • Abstract Number: 1720 • 2019 ACR/ARP Annual Meeting

    Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome

    Gulen Hatemi1, Berna Yurttas 2, Zekayi Kutlubay 3, Tim Cote 4, Semsi Burak Derkunt 4, Yusuf Yazici 5 and Hasan Yazici 6, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University- Cerrahpasa, Behçet's Disease Research Center, Istanbul, Turkey, Istanbul, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 4Silk Road Therapeutics, Washington, DC, USA, Washington, WA, 5New York University School of Medicine, New York, NY, USA, New York, NY, 6Academic Hospital, Istanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Oral ulcers, the hallmark lesion of Behçet’s syndrome (BS) can be disabling and impair eating, drinking and speaking. Despite recent advances in systemic medications…
  • Abstract Number: 918 • 2018 ACR/ARHP Annual Meeting

    A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome

    Emma Dorris1, Fahd Adeeb2, Eoin Cummins3, Sinisa Savic4, Sandy Fraser5 and Anthony G. Wilson6, 1UCD Conway Institute,, UCD Centre for Arthritis Research, Dublin 4, Ireland, 2Department of Rheumatology, University of Limerick, LIMERICK, Ireland, 3School of Medicine, Dublin 4, Ireland, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, United Kingdom, 5Rheumatology, Croom Orthopedic Hospital, Ireland, Limerick, Ireland, 6UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: Bechet’s disease (BD) is a heterogeneous multifactorial auto-inflammatory condition characterized by recurrent episodes of oral and genital ulceration, uveitis and skin lesions, with less…
  • Abstract Number: 1805 • 2018 ACR/ARHP Annual Meeting

    Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease

    Hirotoshi Kikuchi1, Takafumi Tomizuka1, Takahiro Itamiya1, Kurumi Asako1, Tamiko Yanagida1, Hajime Kono2 and Shunsei Hirohata3, 1Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 2Teikyo University School of Medicine, Department of Internal Medicine, Tokyo, Japan, 3Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçetfs disease (BD). This condition is referred to as neuro-BD (NB) and…
  • Abstract Number: 1772 • 2018 ACR/ARHP Annual Meeting

    Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Javier Loricera2, Genaro Graña Gil3, Gerard Espinosa4, Clara Moriano Morales5, Trinidad Pérez-Sandoval6, Manuel Martín-Martínez6, Elvira Díez6, Maria Dolores Garcia Armario7, Ivan Castellví8, Francisca Sivera9, Jaime Calvo-Alén10, Isabel de la Morena11, Francisco Ortiz-Sanjuán12, José Andrés Román-Ivorra13, Ana Pérez Gómez14, Sergi Heredia15, Carolina Díez16, J Alegre17, Amparo Ybáñez17, Javier Narváez18, Ana Turrión Nieves19, Susana Romero-Yuste20, Alejandro Olivé-Marqués21, Águeda Prior22, Esperanza Martínez7, Ignasi Figueras23, Pilar Trénor24, Carmen Gonzalez Vela25, Diana Prieto Peña26, Monica Calderón Goercke26, José Luis Hernández2, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology Division, Complejo Hospitalario Universitario A Coruña. Spain, La Coruña, Spain, 4Department of Autoimmune Diseases, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 6Rheumatology, Hospital Universitario de León. Spain, León, Spain, 7Rheumatology and Dermatology, Hospital Lluís Alcanyís. Valencia. Spain, Valencia, Spain, 8Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau. Barcelona. Spain, Barcelona, Spain, 9Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 10Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 11Hospital General Universitario de Valencia. Spain, Valencia, Spain, 12Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, 13Hospital La Fe. Valencia. Spain, Valencia, Spain, 14Rheumatology, Hospital Universitario Príncipe de Asturias. Alcalá de Henares. Madrid. Spain, Alcalá de Henares, Madrid, Spain, 15Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, Barcelona, Spain, 16Rheumatology, Hospital de El Bierzo. León. Spain, León, Spain, 17Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 18Rheumatology, Hospital Bellvitge. Barcelona. Spain, Barcelona, Spain, 19Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, 20Hospital de Pontevedra. Spain, Pontevedra, Spain, 21Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 22Rheumatology, Hospital Universitari Germans Trias i Pujol. Barcelona. Spain, Barcelona, Spain, 23Rheumatology and Dermatology, Hospital Bellvitge. Barcelona. Spain, Barcelona, Spain, 24Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 25Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 26Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…
  • Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting

    Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road

    Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…
  • Abstract Number: 1773 • 2018 ACR/ARHP Annual Meeting

    Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Vanesa Calvo-Río2, Rosalía Demetrio-Pablo3, Emma Beltrán4, Marina Mesquida5, Alfredo Adan5, Juan Sánchez Bursón Sr.6, M. Victoria Hernández7, Marisa Hernández8, Elia Valls-Pascual9, L. Martinez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, Jose L. García Serrano13, Norberto Ortego Centeno14, Angel Garcia-Aparicio15, Olga Maiz-Alonso16, Ana Blanco17, Cruz Fernandez-Espartero18, Vega Jovaní19, Diana Peiteado20, Elena Aurrecoechea21, Amalia Sanchez-Andrade22, Enrique Minguez23, Carmen Carrasco-Cubero24, Alejandro Olivé-Marqués25, Esteban Rubio-Romero26, Francisco J. Toyos Sáenz de Miera27, David Diaz-Valle28, Joan Miquel Nolla29, Marcelino Revenga Martínez30, Santos Castañeda31, Jose M Herreras32, Alejandro Fonollosa33, Ignacio Torre-Salaberri34, Esperanza Pato Cour35, Juan Cruz36, Carlos Férnandez Cid37, Miriam García-Arias38, Miguel Angel Caracuel-Ruiz39, Carlos Alberto Montilla-Morales40, Antonio Atanes41, Félix Francisco42, Santos Insua43, Senen González-Suárez44, Fernando Gamero45, Luis Francisco Linares46, Fredeswinda I. Romero-Bueno47, Raquel Almodóvar González48, Julio Vázquez49, A. Javier García-González50, Oscar Ruiz Moreno51, Fernando Jiménez-Zorzo51, Javier Manero51, Santiago Muñoz Fernandez52, Fred Antón Pages53, Myriam Gandía54, Francisco Javier López Longo55, Enrique Raya Álvarez56, Paz Rodríguez-Cundín57, Diana Prieto Peña2, Monica Calderón Goercke2, Enar Pons1, José Luis Hernández3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, 7Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 8Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 9Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 10Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 14Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 15Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 16Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, 17Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 18Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 19Rheumatology, Hospital General Universitario de Alicante. Spain, Alicante, Spain, 20Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 21Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 22Rheumatology, Hospital Lucus Augusti. Lugo. Spain, Lugo, Spain, 23Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, 24Hospital de Mérida. Spain, Mérida, Spain, 25Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 26Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 27Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 28Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 29Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 31Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 32Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 33Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 34Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 35Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 36Rheumatology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 37Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 38Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, 39Rheumatology service, Hospital Universitario Reina Sofía. Córdoba. Spain, Córdoba, Spain, 40Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 41Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 42Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 43Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 44Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 45Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, 46Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 47Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 48Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 49Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, 50Rheumatology, Instituto de Investigación Hospital 12 de octubre. Madrid. Spain, Madrid, Spain, 51Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 52Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, 53Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 54Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 55Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 56Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 57Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain

    Background/Purpose: Uveitis is one of the major causes of disability of Behçet's disease (BD). According to the “Expert panel recommendations” (Ophthalmology. 2014; 121:785-96), anti-TNF therapy…
  • Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting

    Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease

    Ertugrul Cagri Bolek, Alper Sari, Berkan Armagan, Abdulsamet Erden, Levent Kilic, Umut Kalyoncu, Meryem Asli Tuncer, Sedat Kiraz and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…
  • Abstract Number: 1778 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease

    Su Jin Choi1, Doo-Ho Lim2, Ji Seon Oh1, Seokchan Hong1, Yong-Gil Kim1, Chang Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)

    Background/Purpose: Systemic vasculitis is one of the major manifestations of Behcet’s disease (BD). Takayasu’s arteritis (TA) is a chronic vasculitis that primarily affects the aorta…
  • Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients

    Gul Guzelant1, Yilmaz Ozyazgan2, Cem Mat3, Vedat Hamuryudan1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…
  • Abstract Number: 1789 • 2018 ACR/ARHP Annual Meeting

    Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey

    Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: Organ-specific patient-reported outcome (PRO) measures may help management decisions of Behcet’s disease (BD). The aim of this prospective study was to evaluate the factors…
  • Abstract Number: 1810 • 2018 ACR/ARHP Annual Meeting

    Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts

    Floor Kerstens1, Christopher J. Swearingen2, Franktien Turkstra1 and Yusuf Yazici3, 1Amsterdam Rheumatology & Immunology Centre - Reade, Amsterdam, Netherlands, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome (BS) is formally diagnosed using the International Study Group (ISG) criteria, where recurrent oral ulceration and any two other symptoms (recurrent genital…
  • Abstract Number: 1790 • 2018 ACR/ARHP Annual Meeting

    An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study

    Gonca Mumcu1, Adebowale Adesanya2, Aysun Aksoy3, Joice Moraes Faria M Belem4, Natalia Borges Cardin4, Fatma Alibaz-Oner5, Tulin Ergun6, Nevsun Inanc7, Alexandre W.S. Souza8, Wafa Madanat9, Farida Fortune10 and Haner Direskeneli7, 1Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 2Barts and The London, School of Medicine and Dentistry, Institute of Dentistry, Clinical and Diagnostic Oral Sciences, London, UK, London, United Kingdom, 3Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 4Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 5Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Istanbul, Turkey, 6Department of Dermatology, Faculty of Medicine, Marmara University, Istanbul, Turkey, 7Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 8Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, 9Jordan’s Friends of Behcet’s disease Patients Society, Medical department, Amman, Jordan, Amman, Jordan, 10Dental Institute, Barts and The London NHS Trust, London, United Kingdom

    Background/Purpose: Efficacy of current management approaches for oral ulcer treatment in routine clinical practice is insufficiently explored in Behcet’s disease (BD) patients. The aim of…
  • Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis

    Jing Shi1, Chan Zhao2, Jiaxin Zhou3, JinJing Liu1, Fei Gao2, Xiaofeng Zeng4, Meifen Zhang2 and Wenjie Zheng1, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 4Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology